Conclusions: Endogenous inhibition of inflammatory pain is dependent on NK 1 receptor-mediated recruitment of opioidcontaining leukocytes.
MANY cellular inflammatory mediators contribute to the generation of pain. 1, 2 However, leukocyte recruitment also contributes to peripheral antinociception. 3 In complete Freund adjuvant (CFA)-induced inflammation, leukocytes containing opioid peptides (e.g., ␤-endorphin and metenkephalin) migrate to inflamed tissue. After exposure to a cold water swim stress (CWS) or local injection of various releasing agents, opioid peptides can be liberated from leukocytes and bind to nearby opioid receptors on peripheral sensory neurons resulting in unilateral antinociception. [3] [4] [5] Both polymorphonuclear leukocytes (PMNs) and monocytes/macrophages cause opioid-mediated antinociception in different stages of inflammation. 6 -8 Blockade of adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) or selectins inhibits the recruitment of opioid-containing leukocytes into the paw and CWS-induced antinociception. 9 -11 In early stages (i.e., 0 -12 h after CFA injection), chemokines (i.e., CXCR2 ligands) are produced at the site of inflammation, mediate the recruitment of opioidcontaining PMNs, directly trigger the release of opioid peptides from PMNs, and induce peripheral opioid-mediated antinociception. 5, 6 In contrast, at later stages (i.e., 24 -96 h after CFA), molecular mechanisms for the recruitment of opioid-containing leukocytes have not yet been identified. PMNs are predominantly recruited in early inflammation (0 -12 h after CFA), whereas macrophages are the principal leukocyte subpopulation at later stages (beyond 24 h after CFA). 8 Leukocyte recruitment is classically mediated by chemokines, but other mediators, such as complement or neuropeptides, can also act as chemoattractants. Substance P is one of the neuropeptides and was originally described as a mediator in pain transmission in the central nervous system and in neurogenic inflammation in peripheral tissue.
12, 13 Three neurokinin (NK 1-3 ) receptors have been identified. Substance P preferentially binds to NK 1 receptors.
14,15 NK 1 receptors are expressed on neurons in the peripheral and central nervous system as well as on leukocytes, endothelial cells, and keratinocytes. 16 -18 Neurokinin receptor agonists enhance leukocyte migration by three distinct mechanisms: (1) direct chemotactic effects on monocytes and PMNs, 19 -22 (2) binding to NK receptors on endothelial cells and increasing the expression of ICAM-1 and several selectins, 17, 23, 24 and (3) augmentation of local chemokine production (e.g., CC chemokine ligand 2 [CCL2]; synonym: monocyte chemoattractant protein 1). 25 In this study, we examined whether the blockade of NK 1 receptors (1) impairs opioid-mediated peripheral antinociception; (2) reduces recruitment of opioid-containing leukocytes; and (3) influences endothelial adhe-sion molecule expression, local chemokine production, and/or migration of PMNs or monocytes/macrophages at 24 or 48 h of CFA inflammation. To further characterize the site of action of NK 1 receptor agonists, we used systemic administration of blood-brain barrier-penetrating (L-733,060) and nonpenetrating NK 1 receptor antagonists (SR140333) as well as intrathecal injection.
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Materials and Methods
Animals and Model of Inflammation
Animal protocols were approved by local authorities and are in accordance with the guidelines of the International Association for the Study of Pain. 29 Male Wistar rats weighing 180 -240 g were injected with 150 l CFA (Calbiochem, La Jolla, CA) into the right hind paw (intraplantar) during brief isoflurane anesthesia and developed an inflammation confined to the inoculated paw. Experiments were conducted at 0 -48 h after inoculation of CFA. All further injections were also performed during brief isoflurane anesthesia.
Measurement of Paw Pressure Threshold
Mechanical nociceptive thresholds were assessed using the paw pressure algesiometer (modified RandallSelitto test; Ugo Basile, Comerio, Italy). 30 Rats were handled for 4 days before testing. On the day of testing, rats were held under paper wadding, and incremental pressure was applied via a wedge-shaped, blunt piston onto the dorsal surface of the hind paw by an automated gauge. The pressure required to elicit paw withdrawal, the paw pressure threshold, was recorded (cutoff at 250 g). The average of three trials, separated by 10-s intervals, was calculated. The same measurement was performed on the contralateral paw in alternated sequence to preclude order effects. To examine endogenous mechanisms of antinociception, paw pressure thresholds were determined at baseline conditions and 1 min after swimming in 2°-4°C cold water for 1 min. 8 An increase in paw pressure threshold was interpreted as mechanical antinociception. All behavioral experiments were performed by an examiner blinded to the treatment protocol.
Implantation of Spinal Catheters
Implantation was performed under continuous isoflurane anesthesia as described. 31 In brief, a 150-mm polyethylene tube (PE 10; Portex, Hythe, United Kingdom) was inserted intrathecally for 25 mm in cervical direction through an incision at the L3-L4 level. During the recovery period of 2 days, animals showing neurologic damage (e.g., paralysis of the hind limbs) were excluded from the study. To ensure intrathecal localization of the catheter, 10 l lidocaine, 2% (Braun, Melsungen, Germany), followed by a 10-l solvent flush was applied, and the animals were monitored for development and reversal of paralysis of both hind limbs.
Fluorescence-activated Cell Sorting
Antibodies. All hematopoietic cells were stained by mouse anti-rat CD45 Cy5 phycoerythrin monoclonal antibody (clone OX-1, identifies the leukocyte common antigen, 4 g/ml; BD Biosciences, Heidelberg, Germany). 32 PMNs were identified by mouse anti-rat RP-1 phycoerythrin monoclonal antibody (12 g/ml). Macrophages were stained by mouse anti-rat CD68 fluorescein isothiocyanate monoclonal antibody (formerly called ED1; 2 g/ml; Serotec, Oxford, United Kingdom). Opioid-containing cells were labeled by mouse 3E7 monoclonal antibody (recognizing the pan opioid sequence, 20 g/ml; Gramsch Laboratories, Schwabhausen, Germany) followed by rabbit anti-mouse immunoglobulin (Ig)G 2aϩb phycoerythrin antibody (15 g/ml; BD Biosciences).
5,7 NK 1 receptor was stained by rabbit anti-rat NK 1 receptor serum (1:100; Chemicon, Hampshire, United Kingdom) at 4°C for 30 min and subsequently by goat anti-rabbit IgG-fluorescein isothiocyanate antitbody (15 g/ml; Vector Laboratories, Burlingame, CA). Specificity of staining was controlled by isotype-matched control antibodies (mouse IgG 2a , 20 g/ml, BD Biosciences; and rabbit IgG 4 g/ml, Santa Cruz, Santa Cruz, CA).
Leukocyte Staining. Cell suspensions from paw tissue were prepared and stained as described. 5, 7, 32 Briefly, subcutaneous paw tissue was enzymatically digested and was pressed through a 70-m nylon filter (BD Biosciences). Staining with anti-rat CD45 Cy5 phycoerythrin was done without permeabilization. For intracellular stains using 3E7, anti-rat-CD68 fluorescein isothiocyanate, and anti-rat RP-1 phycoerythrin, cells were fixed with 1% paraformaldehyde and permeabilized with saponin buffer. Permeabilized cells were incubated with the aforementioned primary and secondary antibodies. Replacement of the primary antibodies with isotype-matched irrelevant antibodies was used for negative controls.
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To calculate absolute numbers of cells per paw, fluorescence-activated cell sorting events from fluorescent TruCOUNT beads and CD45 ϩ stained cells were collected simultaneously, and the number of CD45 ϩ cells per tube was calculated accordingly. For quantification, 70,000 fluorescence-activated cell sorting events were acquired. Data were analyzed using CellQuest software (all BD Biosciences).
Enzyme-linked Immunosorbent Assay
All experiments were performed 0 -48 h after intraplantar injection of CFA. Paw tissue was retrieved, the skin was removed, and subcutaneous tissue was cut into small pieces and processed as described. 6 Substance P, CXC chemokine ligand 1 (CXCL1; synonym: keratinocyte-derived chemokine), CCL2, and interleukin-1␤ (IL-1␤) concentrations were measured by commercially available sub-stance P, mouse CXCL1, rat CCL2, and rat IL-1␤ enzymelinked immunosorbent assay kits according to manufacturers' instructions (Bachem/Peninsula, London, United Kingdom; Biosource International, Nivelles, Belgium; and R&D, Minneapolis, MN, respectively). To measure CXCL1, a rat CXCL1 peptide standard was used as described. 6 Optical density was measured by Spectra Max (Molecular Devices, Ismaning, Germany). Data were analyzed by the Softmax program (Molecular Devices).
Immunofluorescence
The expression of ICAM-1 and NK 1 receptor in inflamed paw tissue was analyzed in rats (n ϭ 5/group) treated with NK 1 receptor antagonists immediately before induction of inflammation and in control animals. Twenty-four hours later, rats were deeply anesthetized with halothane and perfused transcardially (0.1 M phosphate-buffered saline [PBS], followed by fixative solution: PBS containing 4% paraformaldehyde, pH 7.4). The skin with adjacent subcutaneous tissue was removed from both hind paws, postfixed for 30 min at 4°C in the fixative solution, and cryoprotected overnight at 4°C in PBS containing 10% sucrose. The tissue was embedded in Tissue Tek compound (OCT; Miles, Elkhart, IN), frozen, cut into 7-m sections, mounted onto gelatincoated slides, and processed for immunofluorescence. 33 The sections were incubated with mouse anti-ICAM-1 (1:200) alone or in combination with rabbit polyclonal anti-NK 1 receptor antibody (1:500) and then with secondary antibodies. After incubation with primary antibodies, the tissue sections were washed with PBS and then incubated with the appropriate secondary antibodies: a Texas red conjugated goat anti-rabbit antibody in combination with fluorescein isothiocyanate conjugated donkey anti-mouse. The sections were then washed with PBS, mounted in Vectashield or Vectashield mounting media containing 4=,6 diamidino-2-phenylindole (DAPI) (both Vector Laboratories, Burlingame, CA), and viewed under Zeiss LSM510META confocal laser scanning system (Carl Zeiss Imaging, Thornwood, NY). To demonstrate specificity of staining, the following controls were included as mentioned in details elsewhere 10 by omission of either the primary antisera/antibodies or the secondary antibodies. Cell types were identified based on morphologic criteria. The number of ICAM and NK 1 receptor expression in endothelial cells was quantified by an observer blinded to the experimental protocol using a Zeiss microscope (objective 20ϫ). 10 The mean number of ICAM-or NK 1 receptor-positive vessels per section was calculated from counting 3 sections per animal and 5 squares (384 mm 2 ).
Experimental Protocols
Systemic Application of Nk 1 Receptor Antagonists. Rats were injected intraperitoneally every 12 h with 20 mg/kg L-733,060 (dissolved in sterile water and further diluted in up to 500 l normal saline; Tocris, Bristol, United Kingdom) or 10 mg/kg SR140333 (dissolved in dimethyl sulfoxide and further diluted in up to 500 l normal saline; Sanofi, Paris, France). Doses were chosen based on previous publications 34, 35 and our pilot data. Control animals received solvent only (sterile water or dimethyl sulfoxide in normal saline, respectively). CFA was injected intraplantarly after the first injection, and experiments were performed 24 -48 h later.
Intrathecal Application of Nk 1 Receptor Antagonists. Separate groups of rats were injected intrathecally with 0.5 mg/kg L-733,060 (20 l every 12 h) followed by 10 l NaCl (0.9%) flushes. 36 Doses were chosen in pilot experiments and did not produce any toxic effects. Control animals received solvent only. Immediately after the first injection, paw inflammation was induced by CFA, and tissue was harvested 24 h later.
Statistical Analysis
Data are presented as raw values or percentage control of baseline (mean Ϯ SEM). Missing values are due to injection-related hematoma formation distorting fluorescence-activated cell sorting quantification of leukocyte subpopulations or due to accidental death by isoflurane overdose. Normally distributed data were analyzed by t test. Otherwise, the Mann-Whitney rank sum test was used. Multiple measurements were analyzed by one-way analysis of variance for normally distributed data and by two-way repeated-measures analysis of variance when dependent and independent factors were present. Post hoc comparisons were performed by the Student-Newman-Keuls and Holm-Sidak method, respectively. Differences were considered significant if P Ͻ 0.05. 1 Receptor Antagonists Neurokinin-1 receptor blockade did not significantly change baseline paw pressure threshold in inflamed ( fig.  1 ) or noninflamed paws (data not shown). At 24 h of inflammation, CWS-induced antinociception was significantly reduced by both intraperitoneal L-733,060 and intraperitoneal SR140333 treatments (figs. 1A and B), but not by intrathecal L-733,060 ( fig. 1C) . Furthermore, systemic treatment with L-733,060 did not alter baseline hyperalgesia at 48 h of inflammation, whereas it significantly reduced CWS-induced antinociception (table 1) .
Results
Stress-induced Antinociception Is Reduced by NK
Recruitment of Opioid-containing Leukocytes Is Reduced by Blockade of NK 1 Receptors
Cold water swim stress-induced antinociception is mediated by opioid-containing leukocytes at the site of inflammation. 8, 30 In the inflamed paw, 213 * P Ͻ0.05, baseline-cold water swim stress (CWS) (F ϭ 172.2), † P Ͻ 0.05, drug ϫ baseline-CWS (F ϭ 6.9), two-way repeated-measures analysis of variance (n ϭ 6/group). 
Discussion
In this study, we demonstrated that NK 1 receptor antagonists (1) impaired stress-induced peripheral opioidmediated antinociception but did not alter baseline inflammatory hyperalgesia and (2) reduced migration of opioid-containing leukocytes without changing expression of ICAM-1 on endothelial cells or local chemokine/ cytokine production. Systemic administration of bloodbrain barrier-penetrating (SR140333) and nonpenetrating (L-733,060) NK 1 receptor antagonists was equally effective, but intrathecal injection (L-733,060) was ineffective. Taken together, NK 1 receptor antagonists seem to act peripherally by directly inhibiting the recruitment of opioid-containing leukocytes to the site of inflammation.
Baseline inflammatory hyperalgesia was not reduced by administration of NK 1 receptor antagonists (figs. 1A and B and table 1). These findings are in line with previous animal studies 15, 37 as well as studies in human pain patients.
12 Intrathecal application of NK 1 receptor antagonists was also ineffective in our study ( fig. 1C ), but it has been reported to reduce hyperalgesia in other models. [37] [38] [39] In those models, antihyperalgesic effects were short lasting (maximum of 6 h after injection), whereas we measured nociceptive thresholds at 24 -48 h of inflammation and 12 h after the last injection of the NK 1 receptor antagonist. Long-lasting antihyperalgesic effects were only achieved by intrathecal injection of saporin-conjugated substance P that destroys NK 1 receptor-expressing spinal neurons. 40 Inflammatory hyperalgesia is induced by pronociceptive mediators, 2,41 including cytokines (e.g., IL-1␤ 42 ) and chemokines (e.g., CXCL1 43 and CCL2 44, 45 ). In our studies, NK 1 receptor blockade did not change the local expression of representative hyperalgesic cytokines or chemokines (table  3) , in line with the unaltered baseline nociceptive thresholds ( fig. 1 and table 1) .
In contrast to this lack of change in baseline hyperalgesia, stress (CWS)-induced antinociception was reduced by NK 1 receptor antagonists (figs. 1A and B and table 1). Our previous studies demonstrated that this form of antinociception is mediated by opioid peptide release from leukocytes at the site of inflammation and is fully blocked by opioid receptor antagonists in late stages of inflammation. 8, 30, 46 In the current study, we observed a comparable decrease in opioid-containing leukocytes in the inflamed paw using both blood-brain barrier-penetrating (L-733,060) and nonpenetrating (SR140333) NK 1 receptor antagonists, whereas intrathecal injection (L-733,060) was ineffective. The intrathecally injected dose of L-733,060 was previously used in rats and was shown to effectively inhibit NR2B tyrosine phosphorylation in the spinal cord in the CFA model. 36 In addition to intrathecal injection of L-733,060, we also examined intrathecal injection of SR140333 (up to 6 g/kg). This treatment did not reduce migration of opioid-containing leukocytes or stress-induced antinociception either, but we did not present the data because we observed neurotoxicity (e.g., paralysis) at the highest doses. CWS-induced antinociception is mediated exclusively by locally secreted opioid peptides in subcutaneous inflammation. 30, 47 In another paradigm, swim stress has been shown to involve IL-1 receptor activation, 48 but major differences exist between the two models: (1) presence versus absence of inflammation, (2) species (rats vs. mice), (3) type of swim stress (cold vs. warm water), and (4) tests of nociception (Randall-Selitto vs. hot plate). In particular, in our model CWS-induced antinociception cannot be blocked by an antibody against IL-1 or by an IL-1 receptor antagonist, indicating that this form of antinociception is not IL-1 dependent. 49 Taken together, our data show that NK 1 receptor antagonist treatment correlates with impaired recruitment of opioid-containing leukocytes as well as a decrease in opioid-mediated antinociception. This seems to involve a peripheral site of action (i.e., outside the central nervous system). Conceivably, peripheral NK 1 receptors could be blocked on leukocytes, endothelial cells. or peripheral sensory neurons.
To further elucidate the mechanisms of reduced migration of opioid-containing leukocytes, we measured substance P content and NK 1 receptor expression in the inflamed paw. Local substance P content increased during CFA-induced inflammation ( fig. 3A) . Potential sources of substance P are the peripheral sensory neurons and infiltrating leukocytes. 13, 50, 51 In addition to increased substance P amounts, we detected NK 1 receptor expression on all infiltrating leukocytes, on neurons, and on endothelial cells (figs. 3B-D), confirming previous studies. 16, 17, 20, 52 While neurogenic inflammation contributes to leukocyte infiltration, it is unclear whether blockade of NK 1 receptors on peripheral sensory neurons influences leukocyte recruitment. [53] [54] [55] However, NK 1 receptors have previously been shown to enhance leukocyte recruitment by increasing adhesion molecule expression on endothelial cells, 17, 23, 24 by augmenting chemokine production 25 or by directly inducing chemotaxis of leukocytes. 19 -22 Adhesion molecules (i.e., ICAM-1, selectins, and integrins) have previously been shown to mediate the recruitment of opioid-containing leukocytes, and their blockade can impair peripheral opioid-mediated antinociception during CFA-induced inflammation. 9, 11 In the current study, expression of ICAM-1 on endothelial cells was increased at later stages of inflammation (24 h after CFA; table 2). Neither the CFA-induced up-regulation of Data are presented as mean Ϯ SEM. P Ͻ 0.05, differences between chemokines/cytokine, P Ͼ 0.05 for drug and drug ϫ chemokines/cytokine, two-way repeated-measures analysis of variance (F ϭ 36.7, n ϭ 6).
CCL2 ϭ CC chemokine ligand 2; CFA ϭ complete Freund adjuvant; CXCL1 ϭ CXC chemokine ligand 1; IL-1␤ ϭ interleukin-1␤.
ICAM-1 nor that of NK 1 receptors on endothelial cells was altered by peripheral NK 1 receptor blockade ( fig. 4 and table 2). Previous in vitro studies have demonstrated that substance P increased the expression of ICAM-1 16, 17 as well as NK 1 receptors. 56, 57 In in vivo models of inflammation, the effects of NK 1 receptor antagonists vary between experimental models: They decreased NK 1 receptor but not ICAM-1 expression in a mouse model of pancreatitis. 58 In contrast, they reduced ICAM-1 expression in experimental autoimmune encephalomyelitis. 59 In our model, NK 1 receptor antagonists reduced the recruitment of opioid-containing leukocytes, but they did not alter the expression of ICAM-1 or NK 1 receptors on the inflamed endothelium. We cannot fully exclude the possibility that NK1 receptor antagonists alter the expression of other adhesion molecules such as selectins or integrins and, thereby, impair peripheral antinociception.
As a second hypothesis, NK 1 receptor antagonists might decrease local chemokine production and thereby impair selective leukocyte recruitment. Substance P has been shown to up-regulate chemokine production in leukocytes and epithelial cells in vitro. 60, 61 In experimental pancreatitis, local chemokine expression was reduced by an NK 1 receptor antagonist. 62 We examined a PMN-and a monocyte/macrophage-specific chemokine in our model (i.e., CXCL1 63 and CCL2, 64 respectively), and their expression was not altered by NK 1 receptor antagonists (table 3) . Multiple chemokines are responsible for PMN and monocyte/macrophage recruitment, 65 and alterations in other chemokines might occur after treatment with NK 1 receptor antagonists. Although this possibility cannot be excluded, our previous study demonstrated that PMN-specific chemokines (i.e., CXCR2 ligands) were regulated as a group and did not show relevant differences between individual chemokines. 6 Taken together, in our model NK 1 receptor antagonists reduce the migration of opioid-containing leukocytes, but this effect does not seem to be mediated through alterations in adhesion molecule expression on endothelial cells or in local chemokine production.
Third, substance P binding to NK 1 receptors on leukocytes might directly induce migration of opioid-containing leukocytes. This migration might be reduced by NK 1 receptor blockade. Several studies demonstrated that NK 1 receptor agonists induce chemotaxis of PMNs and monocytes/macrophages in vitro. 19, 66, 67 Previous studies have shown that PMNs and monocyte/macrophage migration to the site of inflammation is impaired after treatment with NK 1 receptor antagonists or in NK 1 receptor-deficient mice. 20, 24, 68, 69 In line with these studies, the number of infiltrating macrophages and PMNs as well as of opioid-containing leukocytes was reduced in our model (figs. 2 and 5 and table 4).
In conclusion, we have shown that NK 1 receptor antagonists reduce the recruitment of opioid-containing leukocytes into the inflamed paw and thereby impair opioid-mediated antinociception in CFA inflammation. NK 1 receptor agonists such as substance P seem to directly induce preferential recruitment of opioid-containing monocytes/macrophages while no indirect effects (i.e., alterations in adhesion molecule expression or chemokine production) are observed. Most likely, NK 1 receptor antagonists act directly on NK 1 receptor-expressing, opioid-containing leukocytes, but the effects might also be mediated indirectly through NK 1 receptors on peripheral neurons. Taken together, NK 1 receptor agonists are important in the recruitment of opioid-con- Macrophages, % 100 Ϯ 7.1 42.7 Ϯ 9.8* PMNs, % 100 Ϯ 13.7 67.3 Ϯ 10.4* Data are presented as percentage control of baseline Ϯ SEM.
* P Ͻ 0.05 for drug (F ϭ 8.2), P Ͼ 0.05 for leukocyte subpopulation and drug ϫ leukocyte subpopulation, two-way repeated-measures analysis of variance (n ϭ 8/group).
PMNs ϭ polymorphonuclear cells.
taining leukocytes and the generation of peripheral opioid-mediated antinociception. The impairment of endogenous opioid-mediated peripheral analgesia might be an additional explanation for the lack of efficacy of NK 1 receptor antagonist in human studies.
